Frequency of antibody to a virus-induced tumor-associated antigen (AG-4) in Japanese sera from patients with cervical cancer and controls.
Microquantitative complement fixation was used to detect antibody to AG-4, a tumor-associated herpesvirus type 2-induced antigen, in sera from Japanese patients with cervical neoplasia. The prevalence of antibody to AG-4 in cervical cancer patients is 47% as compared to 7% in control women. That AG-4 antibody is less prevalent in Japanese than in American cancer patients reflects the frequency of genital herpesvirus type 2 infections in Japan. These findings confirm the association of AG-4 with cervical cancer in a proportion of Japanese patients with neoplastic disease; they implicate factors other than herpesvirus type 2 in another proportion of cervical cancer patients. The possibility that herpesvirus type 1 is one of these factors is considered.
D000912:Antibodies, Neoplasm / Q000302:isolation & purification*; D000914:Antibodies, Viral / Q000302:isolation & purification*; D002277:Carcinoma / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D003168:Complement Fixation Tests; D005260:Female; D006564:Herpesviridae / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007564:Japan; D008875:Middle Aged; D009500:Neutralization Tests; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M